CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders.
Antel
Jochen
J
Solvay Pharmaceuticals Research Laboratories, Hans-Boeckler-Allee 20, D-30173 Hannover, Germany. jochen.antel@solvay.com
Gregory
Peter C
PC
Nordheim
Ulrich
U
D000818:Animals; D019440:Anti-Obesity Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008659:Metabolic Diseases / Q000150:complications / Q000517:prevention & control*; D008958:Models, Molecular; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000737:chemistry
D019440:Anti-Obesity Agents; D043884:Receptor, Cannabinoid, CB1